MALVERN, Pa. & ST. LOUIS--(BUSINESS WIRE)--
Galera Therapeutics, Inc., a biotechnology company focused on the development of breakthrough drugs targeting oxygen metabolic pathways in cancer, fibrosis and other human diseases, today announced an $11 million Series A venture capital financing. The round is co-led by New Enterprise Associates (NEA) and Novartis Venture Fund (NVF) and includes Correlation Ventures. Proceeds will be used to expand clinical development of Galera’s small molecule therapeutics.
Galera also named Mel Sorensen, M.D., President and Chief Executive Officer. Dr. Sorensen brings extensive industry experience to Galera, most recently serving as President and CEO of Ascenta Therapeutics and previously holding senior positions at GlaxoSmithKline and Bayer. Robert Beardsley, Ph.D., a founder and acting CEO of Galera prior to Dr. Sorensen’s appointment, will now serve as Executive Chair of the Board of Directors.
“Galera’s dismutase mimetics, as true small-molecule mimics of the critical enzymes in the oxygen metabolic pathways, overcome the limitations of prior approaches to controlling superoxide and its harmful roles in human disease,” said Dr. Beardsley. “This funding and the leadership team we've assembled allow Galera to pursue the exciting and novel therapeutic potential of these pathways. We are delighted to have Mel lead the company as it moves into validating our candidates in critical unmet medical needs.”
Joining Dr. Beardsley on Galera’s Board of Directors are Frank Torti, M.D., and Jim Barrett, Ph.D., of NEA; Campbell Murray, M.D., and Henry Skinner, Ph.D., of Novartis BioVentures, and Dr. Sorensen. The company also announced that it will relocate its headquarters from St. Louis to the Greater Philadelphia area.
“Clinical and pre-clinical studies suggest that the superoxide pathway is a particularly promising target for drug development,” said Dr. Sorensen. “With initial clinical safety tests completed for Galera’s lead candidates, we look forward to confirming its utility, initially in patients with mucositis due to chemoradiation therapy for head and neck cancer, and subsequently in fibrosis and as an anticancer therapeutic.”
“Dismutase enzymes represent an exceptional opportunity for powerful new drugs,” said Dr. Barrett, a General Partner at NEA. "Galera’s small molecule drugs offer the potential to unlock this potent biology.”
"We are enthusiastic about Galera’s drug candidates because of their potentially broad applicability in several serious diseases,” added Dr. Murray, Managing Director at the Novartis Venture Fund. “It is especially exciting to be able to begin clinical validation immediately. We look forward to working with Mel and the Galera team to realize the substantial therapeutic value of their development portfolio.”
Galera Therapeutics, LLC, was founded by an experienced team of drug developers with seed support from BioGenerator, the St. Louis Arch Angels, ABC Laboratories, and the Center for Emerging Technologies. Its dismutase mimetics have demonstrated initial safety in human studies and potent pre-clinical activity, both in attacking tumors and in protecting normal tissue from diseases such as fibrosis and damage such as radiation.
Galera Therapeutics, Inc. (Galera) is dedicated to the development of innovative, effective and safe medicines targeting oxygen metabolic pathways. By focusing on highly selective manipulation of these pathways, Galera believes it can deliver breakthrough drugs to treat and prevent a variety of human diseases. For more information, visit www.galeratx.com
About Galera’s dismutase mimetics:
As true small molecule mimics of the superoxide dismutase (SOD) enzymes, Galera’s dismutase mimetics replicate the catalytic rates and highly selective activity of the three naturally occurring human forms that are key components of oxygen metabolic pathways. Catalyzing the conversion of superoxide to hydrogen peroxide, human SOD enzymes and animal analogues have been shown in multiple clinical studies and pre-clinical tests to act as potent protectors of normal tissue from damage due to radiation, chemotherapy, fibrosis and other serious diseases. In addition, genetic and enzyme studies suggest significant anti-tumor effects from increasing SOD activity, both in isolation and in combination with other cancer therapies. Direct use of the enzymes, however, has been impeded by problems with efficient delivery to the necessary sites of action. Invented by the company’s Chief Scientific Officer, Dennis Riley, Ph.D., Galera’s dismutase mimetics overcome these limitations and have already demonstrated excellent activity in pre-clinical models of fibrosis, cancer and radiation damage. Being tightly targeted to only duplicate the activity of SOD enzymes – avoiding other parts of the oxygen metabolic pathways – the dismutase mimetics have already demonstrated excellent safety in single-agent Phase 1 studies.
Quiz: Identify these famous sports personalities?
- J&K seeks Modi apology on beggar state jibe
Jammu, Dec 7 (IANS) The ruling National Conference (NC) Saturday demanded an apology from Bharatiya Janata Party (BJP) prime ministerial candidate Narendra Modi for describing Jammu and Kashmir as a beggar state. Modi, during his maiden public rally in the state's winter capital Jammu Dec 1, said despite huge natural resources, Jammu and Kashmir was always approaching the central government with a begging bowl. In a joint statement, NC leaders said Saturday it was neither a slip of the tongue …
- The entire world is our home: Dalai Lama
New Delhi, Dec 7 (IANS) Tibetan spiritual leader the Dalai Lama said Saturday the homeless should not lose hope because the world is their home. Speaking at an event organised by Aman Biradari, a people's campaign for secularism, justice and caring, the Tibetan leader further said there should be a self of oneness in the world. Urging students to study, the Dalai Lama said it is essential to have faith in oneself and never feel alone. …
- SC panel to examine iron ore stacks before e-auction
Panaji, Dec 7 (IANS) A Supreme Court-appointed committee will Sunday inspect iron ore stacked at a Goa port which will be later slotted for e-auction, a panel member said. Speaking to reporters after meeting state government officials, U V Singh, an Indian Forest Service officer, said that the team would inspect 10 million plus tons of extracted ore iron ore Mormugao Port Trust (MPT) and clear it for e-auctioning. "The committee met Goa government officials today (Saturday) to work out the …
- Indian bioinformatics firm setting up genomics centre in US
Bangalore, Dec 7 (IANS) Leading Indian bioinformatics firm Strand Life Sciences has tied up with the US-based El Camino Hospital to set up a centre for genomics and personalised medicine in San Francisco, the city-based company said Saturday. "The centre at the genomics medicine institute of the hospital in the Bay area of San Francisco will conduct genomic tests in cardiology and oncology for the local community, which has been an early adopter of technology solutions," Strand chief executive …
- Nobel economics winner Fama says risk of global recession in 2014
One of the three Americans who won this year's Nobel prize for economics said bloated public deficits on both sides of the Atlantic meant that recession remained a real risk for 2014. Eugene Fama, who shares this year's 8 million crown prize with Robert Shiller and Lars Peter Hansen, said on Saturday that highly indebted governments in the United States and Europe posed a constant threat to the global economy. "If there is another recession, it is going to be worldwide." Fama, who has been …
IN-DEPTH ANALYSIS & INTERVIEWS
- Four agricultural barons who minted money in the fields
Many Indian lords of the field are raking in money with simple commodities such as potatoes, maize, rice and soybean, with their success attracting big private equity deals at a time when the rest of the ... …
- Jang Bahadur Singh Sangha used tech to make potato a money spinner
Jang Bahadur Singh Sangha has used technology to make the humble potato a money spinner. And he also rules maize. …
- Sanwaria Agro is among one of the fastest wealth creators
Anil Agrawal's Sanwaria Agro has been ranked one of the fastest wealth creators between 2006 and 2011. …
- A Crushing Blow
A delayed cane crushing season in Uttar Pradesh is hurting both the industry and farmers in the country's second-biggest sugar producing state. …
- A portable warmer comes to the rescue of premature babies
A portable warmer developed by two Indian students and their classmates at Stanford University is helping premature babies survive. …
- Smartphone Effect
Smartphone sales continue to grow fast, but feature phone sales have fallen for the first time. …
- Capricorn Food is among the top mango processors in India
Rahoul Jain has made Capricorn Food one of the top mango processors in India. …
- Most Actives
- Price % Gainers
- Price % Losers
Recent Quotes Symbol Price Change % Chg ChartYour most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.You need to enable your browser cookies to view your most recent quotes.
Recent Quotes News
- Sign-in to view quotes in your portfolios.